Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Current Deferred Revenue (2024 - 2025)

Prime Medicine's Current Deferred Revenue history spans 2 years, with the latest figure at $7.8 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue rose 10.32% year-over-year to $7.8 million; the TTM value through Dec 2025 reached $7.8 million, up 10.32%, while the annual FY2025 figure was $7.8 million, 10.32% up from the prior year.
  • Current Deferred Revenue reached $7.8 million in Q4 2025 per PRME's latest filing, up from $7.0 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $9.3 million in Q3 2024 to a low of $7.0 million in Q3 2025.